Hypertension medication from guidelines to practice: A cohort study in western Iran
Foroud Shahbazi
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Department of Clinical Pharmacy, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorFarid Najafi
Research Center for Environmental Determinants of Health, School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorLida Shojaei
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Department of Clinical Pharmacy, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorMohammad Hosein Farzaei
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorYalda Shokoohinia
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Department of Pharmacognosy & Biotechnology, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorYahya Pasdar
Nutritional Sciences Department School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorBehrooz Hamzeh
Research Center for Environmental Determinants of Health, School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorReza Tahvilian
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorWerya Rahimi
Research Center of Oils and fats, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorEbrahim Shakiba
Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorHossein Karim
Kermanshah Cardiovascular Research Center, Kermanshah University of Medical Science, Kermanshah, Iran
Search for more papers by this authorAnnette Dobson
Centre for Longitudinal and Life Course Research (CLLR), School of Population Health, University of Queensland, Queensland, Australia
Search for more papers by this authorNeha Bhatt
Ric Scalzo Institute for Botanical Sciences, Sonoran University of Health Sciences, Tempe, Arizona, USA
Search for more papers by this authorCorresponding Author
Mehdi Moradinazar
Research Center for Environmental Determinants of Health, School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
Correspondence
Mehdi Moradinazar, Clinical Research Development Center Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Email: [email protected]
Search for more papers by this authorForoud Shahbazi
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Department of Clinical Pharmacy, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorFarid Najafi
Research Center for Environmental Determinants of Health, School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorLida Shojaei
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Department of Clinical Pharmacy, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorMohammad Hosein Farzaei
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorYalda Shokoohinia
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Department of Pharmacognosy & Biotechnology, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorYahya Pasdar
Nutritional Sciences Department School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorBehrooz Hamzeh
Research Center for Environmental Determinants of Health, School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorReza Tahvilian
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorWerya Rahimi
Research Center of Oils and fats, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorEbrahim Shakiba
Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Search for more papers by this authorHossein Karim
Kermanshah Cardiovascular Research Center, Kermanshah University of Medical Science, Kermanshah, Iran
Search for more papers by this authorAnnette Dobson
Centre for Longitudinal and Life Course Research (CLLR), School of Population Health, University of Queensland, Queensland, Australia
Search for more papers by this authorNeha Bhatt
Ric Scalzo Institute for Botanical Sciences, Sonoran University of Health Sciences, Tempe, Arizona, USA
Search for more papers by this authorCorresponding Author
Mehdi Moradinazar
Research Center for Environmental Determinants of Health, School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
Correspondence
Mehdi Moradinazar, Clinical Research Development Center Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Email: [email protected]
Search for more papers by this authorAbstract
Purpose
Hypertension (HTN) is one of the most common risk factors for non-communicable chronic diseases. The aim of the current study is to evaluate the prescribing patterns of antihypertensive medications in Kermanshah Province, west of Iran.
Methods
The Ravansar Non-Communicable Diseases (RaNCD) cohort study is the first Kurdish community-based study; subjects' age ranged from 35 to 65 years. In order to examine the use of medications to control blood pressure, participants were asked to bring all prescribed medications to the study center. Treatments were compared with 2013 European Society of Hypertension (ESH)/European Society of Cardiology (ESC) Guidelines for the management of arterial HTN.
Results
From a total of 10 040 participants in RaNCD cohort, 1575 (15.7%) individuals were hypertensive, of whom, 1271 (80.7%) people were aware of their condition. From 1153 (73.20%) people under treatment, 840 (72.8%) had their HTN properly controlled. The most common medications used to treat HTN were losartan (27.5%), metoprolol (14.3%), and captopril (11.9%). Regardless of type of treatment, 49.3% of all patients have received the medication for l 6 ≥ years. The most commonly used drugs were β-blockers and angiotension receptor blockers as 620 (31.0%) and 612 (30.6%), respectively. Multivariable analysis showed that female gender, those receive ≥3 antihypertensive agents, and using preferred combinations were associated with a better blood pressure control. In addition, the probability of hypertension control was less likely with increasing duration of treatment (i.e >6 years) and in obese patients with ≥35 kg/m2.
Conclusions
Even though adherence to the international guidelines was acceptable, improvements can be made for better control of HTN. Therefore, it is imperative to educate healthcare professionals on improving their selection of antihypertensive medications and combination therapy for hypertensive patients.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.
REFERENCES
- 1Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control clinical perspective: a systematic analysis of population-based studies from 90 countries. Circulation. 2016; 134(6): 441-450.
- 2 Organization WH. A Global Brief on Hypertension: Silent Killer, Global Public Health Crisis: World Health Day 2013. World Health Organization; 2013.
- 3Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004; 43(1): 10-17.
- 4Sharma AM, Wittchen H-U, Kirch W, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens. 2004; 22(3): 479-486.
- 5Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003; 139(4): 244-252.
- 6 Collaboration BPLTT. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000; 356(9246): 1955-1964.
- 7Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014; 16(1): 14-26.
- 8Campbell NR, Brant R, Johansen H, et al. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension. 2009; 53(2): 128-134.
- 9James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint National Committee (JNC 8). JAMA. 2014; 311(5): 507-520.
- 10Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. J Am Coll Cardiol. 2018; 71: 109-118.
- 11Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2013; 22(4): 193-278.
- 12Ma J, Lee K-V, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension. 2006; 48(5): 846-852.
- 13Jarari N, Rao N, Peela JR, et al. A review on prescribing patterns of antihypertensive drugs. J Clin Hypertens. 2015; 22(1): 7.
10.1186/s40885-016-0042-0 Google Scholar
- 14Poustchi H, Eghtesad S, Kamangar F, et al. Prospective epidemiological research studies in Iran (the PERSIAN cohort): rationale, objectives and design. Am J Epidemiol. 2017; 187(4): 647-655.
- 15Eghtesad S, Mohammadi Z, Shayanrad A, et al. The PERSIAN cohort: providing the evidence needed for healthcare reform. Arch Iran Med. 2017; 20(11): 691-695.
- 16 Organization WH. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008. 2011.
- 17McClave AK, McKnight-Eily LR, Davis SP, Dube SR. Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 National Health Interview Survey. Am J Public Health. 2010; 100(12): 2464-2472.
- 18Ryan H, Trosclair A, Gfroerer J. Adult current smoking: differences in definitions and prevalence estimates—NHIS and NSDUH, 2008. J Environ Public Health. 2012; 2012: 1-11.
10.1155/2012/918368 Google Scholar
- 19Roberto F. 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens. 2013; 31: 1281-1357.
- 20Mansia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007; 16(3): 135-232.
- 21Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014; 63: 2889-2934.
- 22Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017; 33(5): 557-576.
- 23Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017; 2017: 24430.
- 24Kuyper LM, Khan NA. Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol. 2014; 30(5): S47-S53.
- 25Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007; 1:CD002003.
- 26Poirier L, Tobe SW. Contemporary use of β-blockers: clinical relevance of subclassification. Can J Cardiol. 2014; 30(5): S9-S15.
- 27Wright JT, Bakris GL, Bell DS, et al. Lowering blood pressure with β-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI trial. J Clin Hypertens. 2007; 9(11): 842-849.
- 28Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Group GD. Management of hypertension: summary of NICE guidance. BMJ. 2011; 343(aug25 2):d4891.
- 29Members ATF, Mancia G, Fagard R, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28): 2159-2219.
- 30Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012; 59: 1110-1117.
- 31Liu F-C, Tsai H-I, Yu H-P. Organ-protective effects of red wine extract, resveratrol, in oxidative stress-mediated reperfusion injury. Oxidative Med Cell Longev. 2015; 2015: 1-15.
- 32Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community. J Clin Hypertens. 2014; 16(1): 14-26.
- 33Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille M-H, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients novelty and significance: a matched cohort study. Hypertension. 2013; 61(2): 309-318.
- 34Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010; 4(1): 42-50.
- 35Patel A, Group AC. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590): 829-840.
- 36Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the very elderly trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015; 13(1): 78.
- 37Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the study on cognition and prognosis in the elderly (SCOPE). J Am Coll Cardiol. 2004; 44(6): 1175-1180.
- 38Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359(23): 2417-2428.
- 39Rimoldi SF, Messerli FH, Chavez P, Stefanini GG, Scherrer U. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. J Clin Hypertens. 2015; 17(3): 193-199.
- 40 The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15): 1547-1559.
- 41Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015; 385(9982): 2047-2056.
- 42Mallat SG, Itani HS, Tanios BY. Current perspectives on combination therapy in the management of hypertension. Integr Blood Press Control. 2013; 6: 69.
- 43Choi HM, Kim HC, Kang DR. Sex differences in hypertension prevalence and control: analysis of the 2010-2014 Korea National Health and nutrition examination survey. PLoS One. 2017; 12(5):e0178334.
- 44Gu Q, Burt VL, Paulose-Ram R, Dillon CF. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and nutrition examination survey 1999–2004. Am J Hypertens. 2008; 21(7): 789-798.
- 45Booth H, Prevost A, Gulliford M. Severity of obesity and management of hypertension, hypercholesterolaemia and smoking in primary care: population-based cohort study. J Hum Hypertens. 2016; 30(1): 40-45.
- 46Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003; 42(5): 878-884.
- 47Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004; 19(4): 357-362.
- 48Vrijens B, Antoniou S, Burnier M, de la Sierra A, Volpe M. Current situation of medication adherence in hypertension. Front Pharmacol. 2017; 8: 100.
